On June 4, Gregory H. Reaman, MD, FASCO, professor of pediatrics at George Washington University School of Medicine and Health Sciences, will receive the Pediatric Oncology Award for his outstanding leadership and achievements in the field.
ASCO’s Partners in Progress Award, to be presented June 4, honors an individual whose patient advocacy has impacted public awareness about cancer or resulted in additional support—either legislatively or fiscally—for cancer research, treatment, prevention, or care.
Dr. Michael P. Link is the recipient of the 2017 Pediatric Oncology Award in recognition of his dedication to advancing the field of pediatric oncology by finding new strategies in the management of common childhood cancers.
A key question that remains unanswered is whether interventions that prevent or reduce risk for severe, disabling, life-threatening, or fatal chronic conditions will mitigate mortality risks for children with cancer.
Intensification of myeloablative therapy with tandem autologous stem cell transplant (ASCT) improved the probability of survival in patients with high-risk neuroblastoma, with no increase in toxicity, according to a Late Breaking Abstract (LBA3).
Susan L. Cohn, MD, a pediatric oncologist at the University of Chicago, is the 2016 recipient of the Pediatric Oncology Award. She is being recognized for her research on neuroblastoma and her leadership role in bringing together scientists worldwide to share their knowledge and expertise.
Cancer affects everyone, and the impact of the disease extends beyond the patient to those close to them. Himself a cancer survivor, Chicago Cubs first baseman Anthony Rizzo founded the Anthony Rizzo Family Foundation to raise money to support families fighting cancer and for cancer research.
Whereas the ties between a cancer diagnosis and financial toxicity are well established, for the first time a correlation has been made between severe financial distress and increased early mortality in patients with cancer.
The randomized phase III TOAD trial investigated whether immediate intervention with androgen deprivation therapy would improve overall survival compared with delayed androgen deprivation therapy in patients with prostate cancer.
LBA2: Efforts to reduce late effects of pediatric cancer treatments have reduced late mortality in those diagnosed more recently, according to new data from the Childhood Cancer Survivor Study. Deaths due to second malignant neoplasms, cardiac toxicity, and other issues have decreased.